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Introduction: Stem cell therapy has recently been introduced to treat patients with type 2 diabetes mellitus
(T2DM). However, no data are available on the efficacy and safety of allogeneic Wharton’s Jelly-derived mesenchymal
stem cell (WJ-MSC) transplantation in patients with T2DM. Here we performed a non-placebo controlled prospective
phase I/II study to determine efficacy and safety of WJ-MSC transplantation in T2DM.
Methods: Twenty-two patients with T2DM were enrolled and received WJ-MSC transplantation through one
intravenous injection and one intrapancreatic endovascular injection (catheterization). They were followed up for
12 months after transplantation. The primary endpoints were changes in the levels of glycated hemoglobin and
C-peptide and the secondary endpoints included insulin dosage, fasting blood glucose (FBG), post-meal blood glucose
(PBG), inflammatory markers and T lymphocyte counts.
Results: WJ-MSC transplantation significantly decreased the levels of glucose and glycated hemoglobin, improved
C-peptide levels and beta cell function, and reduced markers of systemic inflammation and T lymphocyte counts. No
major WJ-MSC transplantation-related adverse events occurred, but data suggest a temporary decrease in levels of
C-peptide and beta cell function at one month after treatment, possibly related to intrapancreatic endovascular
injection.
Conclusions: Our data demonstrate that treatment with WJ-MSCs can improve metabolic control and beta cell
function in patients with T2DM. The therapeutic mechanism may involve improvements in systemic inflammation and/
or immunological regulation.
Trial registration: Chinese Clinical Trial Register ChiCTR-ONC-10000985. Registered 23 September 2010Introduction
Type 2 diabetes mellitus (T2DM) is a metabolic stress
resulting from over-nutrition- and insufficient activity-
induced insulin resistance and β-cell impairment [1,2].
The continuing hyperglycemia results in both micro-
vascular and macrovascular complications. It is impor-
tant for patients to maintain nearly normal glycemic
levels to reduce their risk of diabetic complications.* Correspondence: doctoran2010@hotmail.com
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reproduction in any medium, provided the orAlthough diet control, physical exercise and oral anti-
diabetic drugs are all effective in decreasing hypergly-
cemia, it is difficult for many patients to achieve good
glycemic control depending only on these options, and
most of these patients will eventually require insulin
therapy [3]. However, insulin treatment negatively im-
pacts patients’ daily lives and is frequently associated
with hypoglycemic episodes. Therefore, it is imperative
to explore new strategies for optimal glycemic control or
β-cell replacement.
In recent years, several animal studies and clinical
trials have shown that mesenchymal stem cell (MSC)This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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cell function [4,5]. XY Li and colleagues designed a clinical
study to treat foot disease in patients with type 2 diabetes
mellitus using human umbilical cord blood mesenchymal
stem cells (hUCB-MSC) and indicated that levels of blood
glucose and required insulin dosage were reduced after
hUCB-MSC transplantation accompanied by improved
clinical profiles in diabetic patients [6]. However, the exact
mechanisms of reversing hyperglycemia remain unknown.
A chronic inflammatory process has been demonstrated
in insulin-sensitive tissues and pancreatic islets, which re-
sults in insulin resistance and beta-cell destruction [7,8].
MSCs have demonstrated anti-inflammatory roles in the
treatment of many diseases, such as myocardial infarction
[9], lung injury [10] and systemic lupus erythematosus
[11]. In addition, MSCs play a role in immunoregulation
in the therapy of graft-versus-host disease [12] and auto-
immune disorders [13]. Therefore, we hypothesized that
Wharton’s Jelly mesenchymal stem cell (WJ-MSC) trans-
plantation could be a therapeutic option in T2DM, and
the mechanism may involve improvements in inflamma-
tion and immunoregulation.
On the basis of these observations, we initiated a pro-
spective phase I/II study using WJ-MSCs in patients
with T2DM. In this report, we explored the efficacy and
safety of WJ-MSC transplantation in T2DM patients and
followed up with them for 12 months after treatment.
Methods
Patients
T2DM patients who were diagnosed according to
American Diabetes Association criteria [14] were eli-
gible for participation. The inclusion criteria included
the following: the patients were between the ages of 18
and 70 years, male or female; they had poor glycemic
control with recent anti-diabetic therapies, including
drugs and/or insulin injection for at least three months;
they had a negative result in testing for the glutamic
acid decarboxylase antibody; they had not been preg-
nant or nursing; they had a fasting blood glucose (FBG)
level ≥7.0 mmol/L and HbA1c ≥7%; and they had a good
organic sufficiency, including heart, liver, kidney and
lung, to receive interventional therapy. The exclusion
criteria included the following: acute or chronic in-
fections; any malignancies; hematological diseases or
coagulopathy; known immunosuppressive disease (for
example, acquired immunodeficiency); acute or chronic
pancreatitis; and a history of thoracic or abdominal aorta
diseases. The study protocol was approved by the Com-
mittees of Ethics in Research of the General Hospital of
Chinese People’s Armed Police Forces. All of the patients
provided written informed consent and confirmed their
willingness to receive WJ-MSC injection and perform glu-
cose self-monitoring.Study design
This single-center prospective phase I/II study involved 23
T2DM patients who were enrolled from 1 May 2010 to 1
May 2011. The patients received transplantation twice. Du-
ring and after the treatment, the patients maintained their
baseline anti-diabetic therapy, dietary habits and other life-
style habits. The study had a follow-up period of 12 months
for all of the patients after their last implantation.
Preparation of humanWharton’s Jellymesenchymal stem cells
With the written consent of the parents, fresh human
umbilical cords from both sexes were collected. All um-
bilical cords were obtained from healthy term fetus and
were negative for hepatitis B virus (HBV), hepatitis C
virus (HCV), human immunodeficiency virus (HIV),
Epstein-Barr virus (EBV), cytomegalovirus (CMV) and
syphilis in umbilical cord blood serum. After being dis-
infected in 75% ethanol for 30 seconds, the blood vessels
were removed. WJ-MSCs were prepared as described
elsewhere [11] and all culture conditions adhere to cur-
rent Good Manufacturing Practice (cGMP) standards.
Briefly, the cord was cut into cubes of approximately
0.5 cm3 and centrifuged at 250 g for five minutes. Fol-
lowing removal of the supernatant fraction, these cubes
were washed with serum-free Dulbecco’s modified Eagle’s
medium (DMEM) (Gibco Invitrogen, Carlsbad, CA, USA)
and centrifuged at 250 g for five minutes. After aspiration
of the supernatant fraction, the cubes were placed in a six-
well plate (Corning Enterprises, Corning, NY, USA), cul-
tured in DMEM supplemented with 10% FBS (StemCell
Technologies, Vancouver, BC, Canada) (tested for safety in
the same way as the umbilical cord blood serum), and 100
units/mL penicillin/streptomycin, and incubated at 37°C
in a humidified tissue culture incubator containing 5%
CO2 and 95% air, with a change of culture medium every
three to five days. After 10 days in culture, the cord cubes
were removed from culture and the adherent cells from
individual explanted cord tissue were trypsinized and
passaged into a new flask for further expansion. The
WJ-MSCs harvested from passage 3 were frozen before
characterizing MSC markers with flow cytometry. Flow
cytometry results showed that ≥95% of cells expressed
CD105, CD73, CD44, while the expression of CD45,
CD34, CD31, CD146 and HLA-DR was 2% or less
(Figure 1). One week before transplantation, the cryopre-
served WJ-MSCs were thawed for further culture and
expansion. WJ-MSCs between passages 4 and 6 were used
for transplantation after characterizing MSC markers with
flow cytometry. WJ-MSCs were infused with normal
saline by vein (100 ml) and intervention (15 ml).
Wharton’s Jelly mesenchymal stem cell transplantation
All of the patients were hospitalized and received WJ-
MSC transplantation twice. The cells were infused into
Figure 1 Fluorescence-activated cell sorting analysis of umbilical
cord mesenchymal stem cells. Percentages of all CD105, CD73 and
CD44 were higher than 95%, while none of CD34, CD45, CD31, CD146
and HLA-DR’s percentage was higher than 1%. WJ-MSCs, Wharton’s
Jelly mesenchymal stem cells.
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ectly delivered to the pancreas via the splenic artery
using endovascular catheters on Day 10 the second time.
Each time, the number of cells used was 1 × 106 per kilo-
gram of body weight.
Biochemical and clinical measurements
All of the tests were performed in the Laboratory De-
partment of the General Hospital of Chinese People’s
Armed Police Forces, Beijing, China. The glucose concen-
tration was determined with the glucose oxidase method,
glycated hemoglobin levels were measured using high-
performance liquid chromatography (HPLC) and serum
C-peptide levels were measured with a radioimmunoassay
using commercial kits (Bio-Ekon Biotechnology Co., Ltd.,
Beijing, China). The patients were asked to forgo their
anti-diabetic medication and to fast for eight hours before
the test. The levels of cytokines (IL-1β, IL-6, IL-10 and
TNF-α) in the serum were measured at baseline and
at month 6 after WJ-MSC transplantation using the
BD Cytometric Bead Array (CBA) Human Inflammatory
Cytokines Kit according to the manufacturer's recommen-
dations (BD Biosciences, Franklin, NJ, USA). Peripheral
blood T lymphocyte subset counts were performed at base-
line and six months after WJ-MSC transplantation with
the Human Lymphocyte Subgroup Typing Kit according
to the manufacturer's instructions (BD Biosciences).
Study endpoints
The primary endpoints were changes in the glycated
hemoglobin and C-peptide levels during the oral glucosetolerance test and at 1, 3, 6 and 12 months following
WJ-MSC transplantation. The secondary endpoints in-
cluded changes in the oral anti-diabetic drugs and/or in-
sulin dosage; changes in FBG and 2 h post-meal blood
glucose (PBG) levels; a change in β cell function, as
assessed with the homeostasis model assessment (HOMA)
calculator [15] with fasting glucose and C-peptide [16];
changes in the serum levels of IL-1β, IL-6, IL-10 and
TNF-α as markers of systemic inflammation; and changes
in peripheral blood T lymphocyte counts.
Statistical analysis
All of the data are shown as the mean ± SD. Compari-
sons of time-dependent changes at the time of baseline
and at 1, 3, 6 and 12 months after the treatment were
performed using the repeated-measures ANOVA and
post hoc analysis with the Bonferroni correction was ap-
plied. Correlation analyses were performed using Pearson’s
test. A significant difference was indicated by P <0.05. All
statistical analyses were performed using SPSS (Version
13.0 for Windows, SPSS, Chicago, IL, USA).
Results
Patients
From 1 May 2010 to 1 May 2011, we recruited 23
patients (16 male and 7 female); 1 male patient quit the
study for unexplained reasons. The patients’ mean (±SD)
age was 52.9 ± 10.5 years, and their mean disease dur-
ation was 8.7 ± 4.3 years. Their baseline demographic
and biochemical parameters are summarized in Table 1.
Of the included 22 patients, 17 patients received exogen-
ous insulin infusion, with an average dose of 0.49 ±
0.22 IU/kg/day and a maximum of 1.2 IU/kg/day; 7 of
these 17 patients also received oral anti-diabetic drugs at
the same time. The other patients received only oral
hypoglycemic agents (metformin or acarbose). All of the
patients underwent WJ-MSC transplantation at our hos-
pital. The patients received no other treatments in
addition to their routine diabetic regimen, and they
maintained their regular diets and lifestyle habits during
their hospitalization and follow-up. All of the patients
were followed up for 12 months.
Glycated hemoglobin
The glycated hemoglobin levels showed a progressive
decline after transplantation, with a maximum decrease
3 months after treatment (baseline, 8.20 ± 1.69%; 1 month,
7.08 ± 1.09%; and 3 months, 6.89 ± 0.90%; P <0.01 at
1 month and 3 months compared to the baseline) and
were stable at 6.91 ± 0.96% at the 6-month follow-up
(p < 0.01) and 7.0 ± 0.60% at the 12-month follow-up
(Figure 2A), suggesting a long-lasting effect of WJ-MSC
treatment.
Table 1 Baseline characteristics of the patients




Body-mass index (kg/m2)* 25.1 ± 2.4
Weight (kg) 70.5 ± 11.7
Glycated hemoglobin (%) 8.20 ± 1.69
Fasting plasma glucose (mmol/L) 7.53 ± 2.67
Fasting C-peptide (ng/mL) 1.29 ± 0.83
Diabetes duration (yrs) 8.7 ± 4.3
Smoking status (%) 4
Cholesterol (mmol/L)
Total 5.08 ± 0.84
HDL 1.08 ± 0.21
LDL 3.13 ± 0.72
TG 2.01 ± 1.63
Creatinine (μmol/L) 61.97 ± 19.93
Blood pressure (mm Hg)
Systolic 134.5 ± 10.3
Diastolic 85.75 ± 6.56
Use of antihypertensive medication (%) 4
History of cardiovascular disease (%) 2




Insulin (alone or with oral drug) 17
*Plus/minus values are means ± SD. The body mass index is the weight in
kilograms divided by the square of the height in meters. BMI, body mass
index; HDL, high-density lipoprotein; LDL, low-density lipoprotein; TG,
total cholesterol.
Figure 2 Changes in glycated hemoglobin, fasting glucose and
2 h postprandial glucose levels during the 12-month study
period. A: The changes in glycated hemoglobin levels between
baseline and 1, 3, 6 and 12 months. B: Changes in fasting glucose
and 2 h postprandial glucose levels between baseline and 1, 3, 6
and 12 months. The results are shown as the mean ± S.D. *P <0.05
compared with pretreatment; **P <0.01 compared with pretreatment.
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The fasting glucose levels showed a downward trend
at different times after intervention, with a maximum
decrease 6 months after treatment (baseline, 7.53 ±
2.67 mmol/L; 6 months, 7.12 ± 1.81 mmol/L; P <0.05
at 6 months compared to the baseline) and were sta-
ble at 7.18 ± 1.8 mmol/L at the 12-month follow-up
(P <0.05). The oral glucose tolerance test (OGTT) 2 h
postprandial showed a maximum reduction 1 month
after WJ-MSC transplantation and then slowly rebounded
at different time points during the follow-up (baseline,
14.96 ± 4.54 mmol/L; 1 month, 11.43 ± 3.32 mmol/L;
3 months, 12.19 ± 4.24 mmol/L; 6 months, 12.31 ±
3.67 mmol/L; and 12 months 12.25 ± 3.83 mmol/L; P <0.05
at 1-, 3-, 6-month and 12-month follow-ups compared to
the baseline) (Figure 2B).C-peptide levels
The fasting serum C-peptide levels first decreased at
month 1 and then progressively increased until they
reached their peak value at month 6, again slightly
decreased at month 12 (baseline, 1.29 ± 0.83 ng/mL;
1 month, 1.03 ± 0.93 ng/mL; 3 months, 1.49 ± 0.94 ng/mL;
6 months, 1.95 ± 1.3 ng/mL; and 12 months, 1.86 ±
1.0 ng/mL; P <0.05 at the 6-month and 12-month
follow-up compared to the baseline) (Figure 3A). We
also detected the OGTT 2 h postprandial C-peptide
levels at different times after implantation, but there
was no significant difference compared to the baseline
during any of the follow-up periods.Beta-cell function
The values of fasting glucose and C-peptide in 12/22 pa-
tients were within model (HOMA) limits. HOMA-2B in-
creased significantly from 65.99 ± 23.49% at baseline to
98.86 ± 43.91% at the 6-month follow-up (P <0.05) and
86.0 ± 37.1% at the 12-month follow-up (Figure 3B),
Figure 3 Changes in C-peptide levels and beta-cell secretory
function during the 12-month study period. A: The changes in
fasting C-peptide levels and OGTT 2 h postprandial C-peptide levels
between baseline and 1, 3, 6 and 12 months. B: Beta-cell secretory
function was assessed with HOMA-2B. The results are shown as the
mean ± S.D. *P <0.05 compared with pretreatment. HOMA,
homeostasis model assessment; OGTT, oral glucose tolerance test.
Figure 4 Changes in daily insulin requirements over time. This
figure shows the insulin requirements of T2DM patients at pre-
operation and 1, 3, 6 and 12 months post-transplantation. The results
are shown as the mean ± S.D. *P <0.05 compared with pretreatment.
The analysis included 17 patients that received exogenous insulin at
months 0, 1, 3, 6 and 12. T2DM, Type 2 diabetes mellitus.
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the 1-month and 3-month follow-ups.Insulin requirement and oral hypoglycemic drugs
After WJ-MSC infusion, the 17 patients who were recei-
ving insulin therapy had a gradual reduction in insulin
requirement (baseline, 0.49 ± 0.22 IU/kg/day; 1 month,
0.34 ± 0.20 IU/kg/day; 3 months, 0.27 ± 0.25 IU/kg/day;
6 months, 0.20 ± 0.17 IU/kg/day; and 12 months 0.23 ±
0.19 IU/kg/day; P <0.05 at 1-, 3-, 6-month and 12-
month follow-up compared to the baseline) (Figure 4).
Insulin suspension occurred for 7 of 17 (41%) patients
after stem cell transplantation, ranging from two months
to six months after treatment (3 ± 1.9 months). These
patients remained insulin-free without re-use for a mean
time of nine months (9.3 ± 3.8 months) until the last
follow-up. In total, 5 of 17 (29%) patients had a reduc-
tion in insulin requirement by ≥50%, whereas 1 patient
had to resume insulin use at the pretreatment dosage
after six months of discontinuation. In the remaining
five patients who received insulin treatment, the dosage
of insulin decreased to different degrees, except for onepatient who was a non-responder. In total, one of five
patients who received oral anti-diabetic drugs became
completely drug-free three months after treatment with-
out re-use and had good control of blood glucose with
only diet and exercise intervention. The time of drug
discontinuance was nine months until the last follow-up.
The remaining four patients had a reduction of >50% in
their oral drug requirement.Immunologic tests
As shown in Figure 5A, there was a decrease in the
numbers of T lymphocytes, including CD3+, CD4+ and
CD8+ cells, from 1,234 ± 477, 756 ± 339 and 412 ± 177
per cubic millimeter before transplantation to 1,037 ±
300, 621 ± 156 and 379 ± 135 (P <0.05 for the CD3+ and
CD4+ T lymphocytes compared to the baseline) per
cubic millimeter six months after transplantation, respec-
tively, in all 22 patients who received immunologic tests.
The correlation between the change in the levels of fasting
C-peptide and the counts of CD3+ T lymphocytes was
r2 = -0.550 (P = 0.042). The changes in the numbers of
CD4+ and CD8+ T lymphocytes were not significantly
correlated with changes in fasting C-peptide levels.Markers of systemic inflammation
We chose six months as the follow-up time to examine
the changes in the serum levels of four relevant cyto-
kines: IL-6, IL-10, IL-1β and TNF-α. We found that the
serum levels of interleukin-6 (P <0.05) and interleukin-
1β (P <0.05) were significantly reduced six months after
WJ-MSC transplantation compared with pretreatment in
all 22 patients. The serum levels of TNF-α were also
substantially decreased six months after WJ-MSC treat-
ment (P >0.05), and IL-10 levels were up-regulated at
the same visit (P >0.05) (Figure 5B). The correlation be-
tween the change in levels of fasting C-peptide and IL-6
was r2 = -0.766 (P = 0.001). The changes in IL-1β, TNF-α
Figure 5 The immunologic tests and markers of systemic inflammation. A: The changes in the numbers of CD3+, CD4+ and CD8+ T
lymphocytes between baseline and six months. B: Changes in the serum levels of IL-6, IL-10, IL-1β and TNF-α between baseline and six months.
The results are shown as the mean ± S.D. *P <0.05 compared with pretreatment. The analysis included 22 patients before and six months after
umbilical cord mesenchymal stem cell transplantation.
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in fasting C-peptide levels.
Adverse events
The side effects of WJ-MSC transplantation included
mild and moderate fever in 3 of the 22 patients, which
generally occurred on the first operative day and spon-
taneously returned to normal levels; subcutaneous he-
matoma at the injection site in one case on Day 1 after
the arterial intervention operation (which resolved after
seven days); and nausea, vomiting and headache in one
patient, who recovered spontaneously within one week.
Data suggest a temporary decrease in levels of C-peptide
and beta-cell function at one month after treatment,
possibly related to intrapancreatic endovascular injec-
tion. The safety of intrapancreatic endovascular delivery
is a concern and deserves further investigation. All 22
patients are still under follow-up for possible late-onset
side effects of the WJ-MSC treatment.
Discussion
In the present study, we document, for the first time, that
WJ-MSC transplantation decreased the level of HbA1c;increased the level of fasting C-peptide; decreased the fas-
ting glucose level, 2 h postprandial blood glucose level,
insulin requirement and oral hypoglycemic drugs; and
reduced the systemic inflammation and T lymphocyte
counts in patients with T2DM.
HbA1c is a glycemic indicator and reflects the average
blood glucose over the preceding 8 to 12 weeks [17]. We
detected the maximum decrease in HbA1c in the first
three months after WJ-MSC transplantation, and the
maximum decrease in both the fasting glucose levels
and 2 h postprandial glucose levels occurred at the same
time, implying that WJ-MSC treatment can improve gly-
cemic control in a short time. It is noteworthy that the
levels of the fasting serum C-peptide and 2 h postpran-
dial C-peptide decreased to different degrees in this
period. Strangely, we also found that β cell function de-
creased, as assessed with the HOMA calculator, in 12 of
22 patients at one month. The intrapancreatic endovas-
cular injection could cause impairment of the organ in
case one or more of the following events were to occur:
1) puncturing a large artery causing a major bleed; 2)
causing an instant blood-mediated inflammatory reac-
tion (IBMIR) in the pancreatic circulation and 3) causing
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ately lead to a pancreatic infarction, and erase precious
beta cells. The use of a contrast agent during the inter-
vention may facilitate the identification of potential in-
juries to the pancreas. Further investigations are needed
to address the safety concerns of this delivery method.
At this time-point, 17 patients who received insulin ther-
apy had a reduction in their insulin requirement from
0.48 ± 0.21 IU/kg/day at baseline to 0.34 ± 0.20 IU/kg/
day. The most probable reason for this contradictory
phenomenon is that the infused WJ-MSCs rapidly im-
proved general insulin resistance, which led to a reduc-
tion in endogenous insulin secretion and the need for
exogenous insulin injection. At the subsequent three-
month and six-month follow-ups, the levels of fasting C-
peptide increased gradually and reached a peak value at
six months, which suggests that WJ-MSC transplanta-
tion enhanced the basal insulin secretion. The results of
β cell function, as assessed with the HOMA calculator,
in 12 out of 22 patients also verified this conclusion. At
this stage, the fasting glucose levels showed a downward
trend but were not statistically significant. In addition,
the 2 h postprandial glucose levels showed a signifi-
cant decrease compared to the baseline and remained
constant, suggesting a longer lasting effect of WJ-MSC
treatment.
Because the HbA1c and C-peptide of patients who re-
ceived WJ-MSC treatment showed the best control at
the sixth month, we chose the sixth month to examine
the therapeutic mechanism of WJ-MSC in 22 enrolled
patients. Mounting evidence has demonstrated that chro-
nic and low-grade inflammation plays an important role
in the development and progression of T2DM [18]. In-
flammation can not only impair insulin signaling and con-
tribute to insulin resistance [19,20] but can also trigger β
cell apoptosis and reduce insulin secretion [8]. Many pro-
inflammatory cytokines, such as TNF-α, IL-6 and IL-1β,
have been demonstrated to be elevated in T2DM patients
and participate in the development of insulin resistance
[21,22]. Numerous studies have verified that MSCs show
promising therapeutic potential in autoimmune disease
[11] and neurological abnormalities [23] through the
modulation of the inflammatory condition. Our stud-
ies also demonstrated that the levels of pro-inflammatory
cytokines, including IL-6 and IL-1β, were significantly de-
creased six months after WJ-MSC transplantation. CM
Larsen and colleagues found that an IL-1 receptor
antagonist improved glycemia and beta-cell secretory
function accompanied with a reduction in markers of
systemic inflammation, including C-reactive protein
and IL-6. Through correlation analysis, the serum pro-
inflammatory cytokines were not significantly corre-
lated with the improvement in HbA1c [24]. Our data
also did not show a correlation among the levels ofHbA1c and IL-1β and IL-6, but we found a significant
correlation between the changes in the levels of fasting
C-peptide and IL-6, suggesting that reduced systemic in-
flammation may play an important role in improving basal
insulin secretion. We believe that WJ-MSCs may exert
their therapeutic potential partly by regulating systemic
inflammation.
Shawn Winer et al. found that CD4+ T lymphocytes
residing in visceral adipose tissue controlled insulin re-
sistance in mice with diet-induced obesity, and a similar
process occurred in humans. The treatment of obese
wild type (WT) and ob/ob (leptin-deficient) mice with a
CD3-specific antibody or its F(ab’)2 fragment reduced
the predominance of Th1 cells compared to Foxp3+
cells and reversed insulin resistance for months [25].
Ulrich Kintscher et al. showed that pro-inflammatory
T-lymphocytes played an important role in the initi-
ation and perpetuation of adipose tissue inflammation
and the development of insulin resistance (IR) [26].
Our data showed that the numbers of CD3+ and CD4+
T lymphocytes were reduced in 12 of 14 patients three
months after WJ-MSC treatment, and there was a signifi-
cant correlation between the changes in the levels of fast-
ing C-peptide and the numbers of CD3+ T lymphocytes,
suggesting that WJ-MSC transplantation may participate
in the regulation of the immune process and reduce
inflammation and insulin resistance, improving diabetic
symptoms. Future studies are needed to determine the
correlation between the T lymphocyte counts and diabetic
symptoms in more cases.
For MSC delivery, some studies have chosen intraven-
ous delivery [27] or endovascular catheterization [4], and
a few studies have used both approaches. We believe
that the majority of intravenously transplanted MSCs
will be trafficked to the lung and the other peripheral
tissues [28]; thus, the number of MSCs recruited to islets
is limited. Local intra-arterial (IA) injections can en-
hance the accumulation and increase the number of
MSCs in islets. Nevertheless, safety concerns related to
this delivery method will have to be addressed in future
studies. T2DM is a metabolic disease characterized by
insulin resistance and beta-cell dysfunction. Therefore,
we believe that all of the delivery approaches have limi-
tations, and we chose a combination of two approaches
in our study. MSCs injected through intravenous deliv-
ery improve the symptoms of peripheral tissues, and IA
injected MSCs may exert functions in islets. Based on
our study results, we speculate that intravenously infused
MSCs can inhibit systemic inflammation and improve in-
sulin resistance, whereas local intra-arterial injection in-
fused MSCs can improve islet inflammation and reduce
the damage to β cells.
Many studies have reported a therapeutic effect of um-
bilical cord-derived MSCs in a variety of diseases and no
Liu et al. Stem Cell Research & Therapy 2014, 5:57 Page 8 of 9
http://stemcellres.com/content/5/2/57obvious adverse effects were reported [11,29,30]. XY XY
and colleagues designed a clinical study to treat foot
disease in patients with type 2 diabetes mellitus using
hUCB-MSCs and there is no related adverse effect re-
ported [6]. J Hu et al. assessed the long-term effects
of the implantation of WJ-MSCs for new-onset T1DM.
There were no obviously adverse reactions in any of the
patients who completed the study protocol, and no chro-
nic side effects or lingering effects appeared during the
follow-up [29]. Lingyun Sun’ study explored the therapeu-
tic effect of UC-MSCs in severe and treatment-refractory
systemic lupus erythematosus (SLE). No treatment-related
adverse events occurred during or after UC-MSC trans-
plantation, and UC-MSC transplantation was well tole-
rated by all patients [11]. We also have the same results
on the safety of WJ-MSC transplantation with all the
above trials.
Conclusions
These findings suggest that WJ-MSC transplantation may
have a possible therapeutic potential in T2DM. Further-
more, we showed that the therapeutic effect was asso-
ciated with an improvement in β cell function, systemic
inflammation and/or immunological regulation. Further
follow-up and large-scale placebo-controlled clinical stud-
ies are necessary to fully elucidate the role of WJ-MSCs in
the treatment of T2DM.
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